Roggwil, January 21, 2020 – The Ethics Committee of Charité has approved the double-blind study for the tinnitus therapy device tinniwell with Resaphene Suisse AG, ISIN CH0367465439, WKN A2JG91. A total of 60 individuals are participating in the study, and the leadership is entrusted to Prof. Dr. med. Birgit Mazurek. Results are expected for Q4/2020 or Q1/2021.

The double-blind study has the same design as an initial clinical user observation by Dr. med. Johannes Ebbers. In this observation, an average relief of 54% was documented within 4 weeks; one patient even experienced a 100% relief from tinnitus during this period. Resaphene anticipates similar results in the double-blind study based on the aforementioned facts. Should these results be achieved, tinniwell could become the new global standard in tinnitus therapy. Currently, no competitor is known to provide comparable therapy results. In the target markets of Europe and the USA, there are an estimated over 100 million affected patients.

The management of Resaphene expects that if the study is successfully concluded, further institutional investors will participate or the intellectual property will be sold to a hearing aid manufacturer as part of an exit strategy for the existing shareholders. No binding contracts have been concluded so far.

++ About Resaphene Suisse AG

Resaphene Suisse AG, based in Roggwil, Switzerland, is a medical technology company that was founded in 2015 and has been marketing a tinnitus therapy device under the name tinniwell since 2016. Since June 2018, shares have been traded on the Vienna Stock Exchange in the Segment Third Market. Additional distribution companies include Resaphene Deutschland GmbH in Constance, Resaphene UK Ltd. in London, and Resaphene US LLC in the USA.

++ Contact for inquiries:
Resaphene Suisse AG
Bahnhofplatz 5
9322 Egnach
Switzerland

Investor Relations Contact:
Ms. Anke Rauterkus (Chief Executive Officer)
a.rauterkus@resaphene.ch